Anzeige
Meldung des Tages: Die nächsten 10.000 Bohrmeter könnten alles verändern, während andere Explorer noch planen

Jazz Pharmaceuticals News

Aktie
WKN:  A1JS1K ISIN:  IE00B4Q5ZN47 US-Symbol:  JAZZ Branche:  Biotechnologie Land:  Irland
159,06 €
-0,98 €
-0,61%
07:30:39 Uhr
Depot/Watchlist
Marktkapitalisierung *
8,78 Mrd. €
Streubesitz
-
KGV
-
Nachhaltigkeits-Score
37 %
Index-Zuordnung
-
Weiter abwärts? Short handeln - Jetzt mit Hebel 6,50: JU6CB1
Werbung

Jazz Pharmaceuticals News

24.02.26 - PR Newswire
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance PR Newswire
24.02.26 - PR Newswire
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance PR Newswire
17.02.26 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
17.02.26 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire
10.02.26 - PR Newswire
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 PR Newswire
10.02.26 - PR Newswire
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026
Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 PR Newswire
08.01.26 - PR Newswire
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer PR Newswire
06.01.26 - PR Newswire
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit
Ziihera® (zanidatamab-​hrii) Combinations Achieve Unprecedented Results in First-​Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall ...
17.12.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Jazz Pharmaceuticals to Participate in Upcoming Investor Events PR Newswire
17.12.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Events
Jazz Pharmaceuticals to Participate in Upcoming Investor Events PR Newswire
05.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting
Jazz Pharmaceuticals to Present Extensive New Data and Real-​World Evidence Highlighting Epidiolex® (cannabidiol) Outcomes in Treatment-​Resistant Epilepsies at the American ...
02.12.25 - PR Newswire
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-​hrii) Combinations in First-​Line HER2-Positive Locally Advanced or Metastatic ...
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
18.11.25 - PR Newswire
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference PR Newswire
17.11.25 - PR Newswire
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Positive HERIZON-​GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-​hrii) as HER2-Targeted Agent-​of-Choice and Ziihera Combination Regimens as New Standard of Care ...
11.11.25 - PR Newswire
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 PR Newswire
05.11.25 - PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
05.11.25 - PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance PR Newswire
28.10.25 - PR Newswire
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors PR Newswire
22.10.25 - PR Newswire
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 PR Newswire

Newssuche

Videos

newspaper
10.03.26 -10,03%
Technical Trading: DAX Long Chance
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »